Display options
Cite
Imasawa M, Tanabe J, Kashiwagi F, et al. Efficacy and Safety of Switching Latanoprost Monotherapy to Bimatoprost Monotherapy or Combination of Brinzolamide and Latanoprost. Open Ophthalmol J. 2016;10:94-102doi: 10.2174/1874364101610010094.
Imasawa, M., Tanabe, J., Kashiwagi, F., & Kashiwagi, K. (2016). Efficacy and Safety of Switching Latanoprost Monotherapy to Bimatoprost Monotherapy or Combination of Brinzolamide and Latanoprost. The open ophthalmology journal, 1094-102. https://doi.org/10.2174/1874364101610010094
Imasawa, Mitsuhiro, et al. "Efficacy and Safety of Switching Latanoprost Monotherapy to Bimatoprost Monotherapy or Combination of Brinzolamide and Latanoprost." The open ophthalmology journal vol. 10 (2016): 94-102. doi: https://doi.org/10.2174/1874364101610010094
Imasawa M, Tanabe J, Kashiwagi F, Kashiwagi K. Efficacy and Safety of Switching Latanoprost Monotherapy to Bimatoprost Monotherapy or Combination of Brinzolamide and Latanoprost. Open Ophthalmol J. 2016 Mar 07;10:94-102. doi: 10.2174/1874364101610010094. eCollection 2016. PMID: 27073587; PMCID: PMC4800778.
Copy Download .nbib Format: NLM
Share it on

Open Ophthalmol J. 2016 Mar 07;10:94-102. doi: 10.2174/1874364101610010094. eCollection 2016.

Efficacy and Safety of Switching Latanoprost Monotherapy to Bimatoprost Monotherapy or Combination of Brinzolamide and Latanoprost.

The open ophthalmology journal

Mitsuhiro Imasawa, Joji Tanabe, Fumiko Kashiwagi, Kenji Kashiwagi

Affiliations

  1. Department of Ophthalmology, Nirasaki Municipal Hospital, Nirasaki, Yamanashi, Japan; Department of Ophthalmology, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan.
  2. Tanabe Eye Clinic, Kai, Yamanashi, Japan.
  3. Kashiwagi Eye Clinic, Kofu, Yamanashi, Japan.
  4. Department of Ophthalmology, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan.

PMID: 27073587 PMCID: PMC4800778 DOI: 10.2174/1874364101610010094

Abstract

PURPOSE: To prospectively assess the efficacy and safety of switching to bimatoprost monotherapy or brinzolamide and latanoprost combination therapy in patients who had been receiving latanoprost monotherapy.

METHODS: A prospective, open-label study was conducted. Patients with primary open-angle glaucoma or ocular hypertension who had been receiving latanoprost monotherapy for three months or more were enrolled. Bimatoprost was substituted for latanoprost in one eye (BIM group), and brinzolamide was added to the latanoprost in the other eye (BRZ group) simultaneously. The patients underwent examinations at 6 weeks (visit 1) and 12 weeks (visit 2) after changing therapies. Subsequently, the treatments were returned to latanoprost monotherapy. The patients underwent another examination 6 weeks (visit 3) after the return to latanoprost. The parameters examined were intraocular pressure (IOP), conjunctival hyperemia, and corneal epithelial damage.

RESULTS: Twenty-six patients (13 men and 13 women) completed the protocol. Both groups showed a significant IOP reduction at visits 1 and 2 compared with the baseline, with a similar magnitude (BIM group: P = 0.016 at visit 1, P = 0.025 at visit 2, BRZ group: P = 0.0006 at visit 1, P = 0.028 at visit 2). The IOPs at the baseline and on visit 3 were similar in both groups (P = 0.7). The two groups showed no changes in either conjunctival hyperemia or corneal epithelial damage compared with the baseline.

CONCLUSION: Bimatoprost monotherapy and brinzolamide adjunctive to latanoprost similarly reduced the IOP, with no additive adverse effects, compared with latanoprost monotherapy.

Keywords: Bimatoprost; Brinzolamide; Glaucoma; Intraocular Pressure; Latanoprost

References

  1. Surv Ophthalmol. 2001 May;45 Suppl 4:S353-60 - PubMed
  2. Adv Ther. 2006 May-Jun;23(3):385-94 - PubMed
  3. Jpn J Ophthalmol. 2012 Jul;56(4):346-53 - PubMed
  4. Br J Ophthalmol. 2008 Jan;92(1):7-12 - PubMed
  5. J Glaucoma. 2008 Dec;17(8):667-73 - PubMed
  6. Open Ophthalmol J. 2010 Apr 28;4:7-11 - PubMed
  7. Clin Ophthalmol. 2012;6:739-46 - PubMed
  8. Acta Clin Croat. 2010 Dec;49(4):411-9 - PubMed
  9. Am J Ophthalmol. 2003 May;135(5):688-703 - PubMed
  10. J Ocul Pharmacol Ther. 2013 Dec;29(10):876-81 - PubMed
  11. Jpn J Ophthalmol. 2011 Nov;55(6):600-4 - PubMed
  12. Minerva Med. 2013 Aug;104(4):471-85 - PubMed
  13. Surv Ophthalmol. 2001 May;45 Suppl 4:S337-45 - PubMed
  14. Clin Ophthalmol. 2015 Aug 07;9:1429-36 - PubMed
  15. Clin Ther. 2001 Dec;23(12):1969-83 - PubMed
  16. Curr Med Res Opin. 2008 May;24(5):1435-42 - PubMed
  17. Surv Ophthalmol. 2002 Aug;47 Suppl 1:S105-15 - PubMed
  18. J Ocul Pharmacol Ther. 2011 Oct;27(5):499-502 - PubMed
  19. PLoS One. 2015 Oct 20;10(10):e0140601 - PubMed
  20. Clin Ophthalmol. 2012;6:1547-52 - PubMed
  21. Jpn J Ophthalmol. 2012 Jul;56(4):339-45 - PubMed
  22. Br J Ophthalmol. 2009 Mar;93(3):316-21 - PubMed
  23. Ophthalmology. 2016 Jan;123(1):129-40 - PubMed
  24. Pharmacol Rev. 2013 Jul 26;65(4):1135-47 - PubMed
  25. Clin Ophthalmol. 2010 May 14;4:459-66 - PubMed
  26. J Glaucoma. 2008 Apr-May;17(3):233-7 - PubMed
  27. Brain Res. 2009 Dec 15;1303:131-43 - PubMed
  28. J Clin Epidemiol. 2009 Dec;62(12):1279-83 - PubMed
  29. Clin Ophthalmol. 2008 Dec;2(4):703-8 - PubMed
  30. Adv Ther. 2003 Mar-Apr;20(2):121-8 - PubMed
  31. Arch Ophthalmol. 2003 Nov;121(11):1537-9 - PubMed
  32. Ann Pharmacother. 2002 Mar;36(3):504-11 - PubMed
  33. Ophthalmic Res. 2009;42(2):99-105 - PubMed
  34. Curr Med Res Opin. 2007 Mar;23(3):601-8 - PubMed
  35. Clin Ophthalmol. 2009;3:663-70 - PubMed
  36. Graefes Arch Clin Exp Ophthalmol. 2004 Sep;242(9):767-70 - PubMed
  37. Drugs Today (Barc). 2007 Feb;43(2):77-83 - PubMed
  38. Eur J Ophthalmol. 2009 May-Jun;19(3):400-3 - PubMed

Publication Types